EGFR amplification is detectable by next‐generation sequencing (NGS) in approximately 40%–50% of GBM cases1, 2, 3 and 14.4%–26% of GBMs harbor EGFR mutations.2, 3. This evidence concerns the gene EGFR and glioblastoma.